January 23rd, 2023 Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
October 31st, 2022 Ubiquigent obtains exclusive license for UbiSite technology to strengthen its specialist drug discovery services
July 5th, 2022 Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board